Navigation Links
Endologix Announces Pricing of Public Offering of Common Stock
Date:7/30/2009

IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX) today announced that it has entered into an agreement to sell 3,900,000 shares of its common stock in an underwritten public offering at a price to the public of $4.10 per share. The gross proceeds to Endologix, before offering expenses, from the sale of shares are expected to be $15,990,000. The closing of the offering is expected to take place on August 4, 2009. Piper Jaffray & Co. will be the sole manager for the offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on May 8, 2009 that became effective on June 1, 2009. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. When available, copies of the prospectus supplement relating to the offering may be obtained upon request to Piper Jaffray & Co., at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the proposed offering by Endologix. Endologix intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on the current assumptions of the Company's management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements. Factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in greater detail under the heading "Risk Factors" contained in the Company's periodic SEC filings. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. The Company undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

    COMPANY CONTACT:
    Endologix, Inc.
    John McDermott, CEO
    (949) 595-7200
    www.endologix.com

    INVESTOR CONTACTS:
    The Ruth Group
    Nick Laudico (646) 536-7030
    Zack Kubow (646) 536-7020


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix Reports 42% Second Quarter 2009 Revenue Growth
2. Endologix to Report Second Quarter 2009 Financial Results on July 22, 2009
3. Endologix Added to Russell Indexes
4. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
5. Endologix Receives Nasdaq Letter on Director Independence
6. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
7. BD Announces Results for Third Fiscal Quarter
8. Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies
9. The Mills Group LLC Announces ElderCare/PrimePlus Service
10. Tampa Bay Radiation Oncology Announces New Full Service Center at Bruce B Downs
11. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... , ... May 26, 2017 , ... Dr. Alex Rabinovich, ... to announce a new, informational blog post on insurance options. If a Bay Area ... plans may help save time and money. Visiting an in-network provider for a second ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the ... Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... to say, he is "panther quick and leather tough." His love for others is ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: retells the ... of Eden” is the creation of published author, Penelope Colt, mother, trader, horse farmer, artist ... to NYC when she was three. At six, they moved to Dayton, Ohio, where ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several classrooms ... left education officials with a number of critical issues to address before students could ... be accomplished with little or no disruption to class schedules. Second, the project had ...
(Date:5/24/2017)... Ca (PRWEB) , ... May 24, 2017 , ... ... effects and background. Understanind and choosing the most appropriate instruments for research and ... critical in research finding. This webinar will focus on innovations in stereo microscopy ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 2017  Amy Baxter MD, chief executive officer and ... pain relief, was awarded a 2017 Top 40 Healthcare ... recognized at the MM&M Top 40 Healthcare Transformers dinner ... on May 10, 2017. The dinner followed a ... "beyond the pill."  "Innovation goes beyond invention," ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... second quarter ended April 1, 2017 .   GAAP ... compared to the prior year period as the sale ... gain, while non-GAAP diluted EPS of $0.50 increased 6.4%.  ... constant currency terms.  Excluding the effects of blood screening ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
Breaking Medicine Technology: